3 results
Approved WMORecruiting
This research has the goal to determine which treatment is the most effective treatment in terms of prevention of treatment failure, in costs and has the patients preference when comparing PDT, Imiquimod and 5FU.
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMORecruiting
To collect clinical and device performance outcomes data with the ACURATE neo2* Transfemoral Aortic Valve System as used inroutine clinical practice for the treatment of severe calcific aortic stenosis.